ESR1 and breast carcinoma: This meta-analysis was the first to demonstrate risk reductions for soy isoflavones in recurrence in women with estrogen receptor–positive breast cancer and for ENL in breast cancer–specific mortality and node-negative survivors in all-cause mortality.